Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On December 12, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations facility in Srikakulam, Andhra Pradesh. The inspection, conducted from December 4 to December 12, resulted in a Form 483 with five observations, which the company plans to address within the stipulated timeline. This inspection and its outcomes are crucial for the company’s compliance and operational integrity, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It specializes in the development and production of a wide range of pharmaceutical products, including generic medications, active pharmaceutical ingredients, and biologics, primarily focusing on the global market.
Average Trading Volume: 1,110,188
Technical Sentiment Signal: Buy
Current Market Cap: $11.75B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.